Acute Gout Flare Management: Evidence‑Based Recommendations

First‑Line Oral Therapy

• Oral prednisone 30–35 mg once daily for 5 days is recommended as the preferred first‑line treatment for most patients with an acute gout flare; it provides efficacy comparable to NSAIDs and colchicine while offering a better safety profile and lower cost【1】.
• A fixed‑dose regimen of prednisone 30–35 mg daily for 5 days does not require tapering in uncomplicated attacks【2】.
• In patients with severe attacks or polyarticular involvement, a weight‑based regimen of 0.5 mg/kg/day for 2–5 days followed by a 7–10‑day taper can be used【1】.
• A methylprednisolone dose‑pack is an acceptable alternative when preferred by the clinician or patient【1】.

Safety Advantages of Corticosteroids

• Corticosteroids are safer than NSAIDs in individuals with eGFR < 30 mL/min, cardiovascular disease, heart failure, cirrhosis, peptic ulcer disease, or those on anticoagulation【1】.
• The adverse‑event rate with oral corticosteroids is approximately 27 % versus 63 % for NSAIDs【1】.

Alternative Oral Agents

NSAIDs

• Full FDA‑approved anti‑inflammatory doses of any potent NSAID are effective; early initiation is more important than the specific agent chosen【4】.
• Contraindications to NSAIDs include peptic ulcer disease, renal failure (eGFR < 30 mL/min), uncontrolled hypertension, heart failure, and anticoagulation【2】.

Colchicine

• The FDA‑approved regimen is 1.2 mg immediately followed by 0.6 mg one hour later (maximum 1.8 mg)【3】.
• Initiating colchicine within 12 hours of symptom onset yields the greatest efficacy【3】.
• Fatal toxicity can occur in patients with severe renal impairment or when combined with strong CYP3A4/P‑gp inhibitors (e.g., clarithromycin, cyclosporine, ritonavir, ketoconazole)【2】.

Parenteral Steroid Options (When Oral Therapy Is Not Feasible)

• Intramuscular triamcinolone acetonide 60 mg as a single injection provides rapid relief【1】.
• Intramuscular methylprednisolone 40–140 mg (0.5–2.0 mg/kg) is an alternative dosing option【1】.
• Intravenous methylprednisolone 0.5–2.0 mg/kg (≈40–140 mg) can be repeated as clinically indicated【1】.
• Intra‑articular corticosteroid injection is highly effective for mono‑ or oligo‑articular flares involving 1–2 large joints【3】.

Treatment Selection Algorithm

• Contraindications:

  • Active systemic infection → avoid corticosteroids and IL‑1 inhibitors【1】.
  • eGFR < 30 mL/min → avoid NSAIDs and colchicine; use corticosteroids【2】.
  • Concurrent strong CYP3A4/P‑gp inhibitors → avoid colchicine【2】.
  • Cardiovascular disease, heart failure, or peptic ulcer disease → avoid NSAIDs; prefer corticosteroids【1】.

• Joint Involvement:

  • 1–2 accessible large joints → consider intra‑articular injection【3】.
  • Polyarticular or severe attacks → initiate oral prednisone 30–35 mg daily【2】.

• Timing:

  • Initiating therapy within 12–24 hours of flare onset is the single most critical determinant of success, irrespective of the chosen agent【2】.

• Response Monitoring:

  • Inadequate response is defined as <20 % pain reduction within 24 h or <50 % reduction after ≥24 h【1】.
  • If response is inadequate, switch to an alternative monotherapy or add a second agent【3】.

Combination Therapy for Severe or Polyarticular Flares

• Oral corticosteroid plus colchicine, or intra‑articular steroid plus any oral agent, may be used as initial combination therapy in severe attacks【1】.
• Concurrent use of NSAIDs with systemic corticosteroids is contraindicated due to synergistic gastrointestinal toxicity【2】.

Management of Urate‑Lowering Therapy (ULT)

• Established ULT should be continued throughout an acute flare; discontinuation worsens the flare and hampers long‑term control【2】.
• When initiating ULT during or after a flare, prescribe anti‑inflammatory prophylaxis for 3–6 months:
  
  • First‑line prophylaxis: low‑dose colchicine 0.5–0.6 mg once or twice daily【3】.
  • Second‑line prophylaxis: low‑dose prednisone <10 mg/day【1】.

Adjunctive Measures

• Topical ice applied to the affected joint can provide symptomatic relief【3】.
• Weight‑loss programs are recommended for overweight or obese patients to reduce gout burden【3】.

Special Populations

Elderly with Renal Impairment

• Prednisone 30–35 mg daily for 5 days remains the safest option; NSAIDs risk acute kidney injury and colchicine carries fatal toxicity risk in this group【1】.

Patients with Diabetes

• Short‑course corticosteroids may raise blood glucose; close glucose monitoring and proactive adjustment of diabetic medications are advised, but a 5–10‑day course remains appropriate【1】.

Patients Unable to Take Oral Medications

• Parenteral glucocorticoids are strongly preferred over IL‑1 inhibitors or ACTH; IM triamcinolone 60 mg or IV methylprednisolone 0.5–2.0 mg/kg are recommended【3】【1】.

IL‑1 Inhibitors (Last‑Resort Therapy)

• Canakinumab 150 mg subcutaneously is conditionally recommended for patients who have contraindications to all first‑line agents and experience frequent flares; current infection is an absolute contraindication, and the drug is substantially more expensive than corticosteroids【2】【1】.

Common Pitfalls to Avoid

• Delaying treatment initiation markedly reduces the likelihood of successful flare resolution【2】.
• Co‑administration of colchicine with strong CYP3A4/P‑gp inhibitors can be fatal【2】.
• Prescribing NSAIDs to elderly patients with renal impairment, heart failure, or peptic ulcer disease increases risk of adverse events【2】.
• Stopping ULT during an acute flare worsens outcomes【3】.
• Using prednisone doses >10 mg/day for prophylaxis is not recommended【1】.
• Combining NSAIDs with systemic corticosteroids should be avoided due to heightened gastrointestinal toxicity【2】.